Overview
- Description
Herantis Pharma Plc is focusing on clinical-stage biotechnology disease modifying therapies for neurodegenerative diseases. The Company has focused on HER-096 development which is an advanced small synthetic chemical peptidomimetic molecule to treat Parkinson’s disease through a subcutaneous administration, enabling to modify and slow the disease progression in early stages.
- Website
- Country
- Finland
- Sector
- Health Biotechnology